Alcon agrees to acquire STAAR Surgical
The planned acquisition of STAAR includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia with or without astigmatism.
Related Articles
Video: Fellow Eye Data Supports GA Clinical Trial Design
At ASRS, Diana Do, MD, presented results of a post hoc analysis of the OAKS and DERBY trials of geographic atrophy growth rates in untreated…
Cosmetic procedures associated with serious ophthalmologic complications
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.
NICE approves idebenone for LHON in the UK
In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment.
Women in Ophthalmology
Healio brings you highlights from the Women in Ophthalmology Summer Symposium.
Triamcinolone Acetonide–Wrapped Silicone Oil in the Anterior Chamber
This case report discusses a diagnosis of a silicone oil bubble encased in triamcinolone acetonide in the anterior chamber of a patient who underwent retinal…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
This cohort study investigates whether semaglutide prescription is associated with increased risk of nonarteritic anterior ischemic optic neuropathy among patients with type 2 diabetes and…
Clearside Biomedical’s Xipere (triamcinolone acetonide injectable suspension) approved by Health Canada
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.
Glaucoma Today
GT delivers important information on recent research, surgical techniques, clinical strategies, therapeutics, and technology.
Top IRDs to Watch: Choroideremia – Retina Today
Clinical characteristics, diagnosis, and management of this rare condition found primarily in men.
